Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
HAE Haemonetics Corp
- Stocks
- Healthcare
- NYSE: HAE
Price (delayed)
$69.66
Market cap
$3.35B
P/E Ratio
20.92
Dividend/share
N/A
EPS
$3.33
Enterprise value
$4.26B
Haemonetics is a global healthcare company dedicated to providing a suite of innovative medical products and solutions for customers, to help them improve patient care and reduce the cost of
Highlights
The price to earnings (P/E) is 59% lower than the 5-year quarterly average of 50.7 and 30% lower than the last 4 quarters average of 29.7
The company's EPS rose by 44% YoY and by 30% QoQ
The company's quick ratio has shrunk by 58% QoQ and by 31% YoY
The debt has soared by 52% year-on-year
Key stats
What are the main financial stats of HAE
Market
Valuations
Earnings
Shares outstanding
48.04M
Market cap
$3.35B
Enterprise value
$4.26B
Price to earnings (P/E)
20.92
Price to book (P/B)
4.26
Price to sales (P/S)
2.58
EV/EBIT
19.22
EV/EBITDA
12.64
EV/Sales
3.13
Revenue
$1.36B
Gross profit
$748.96M
Operating income
$198.8M
Net income
$167.68M
EBIT
$221.82M
EBITDA
$337.4M
Free cash flow
$144.59M
Per share
Balance sheet
Liquidity
EPS
$3.33
EPS diluted
$3.31
Free cash flow per share
$2.87
Book value per share
$16.34
Revenue per share
$27.04
TBVPS
$27.64
Total assets
$2.45B
Total liabilities
$1.63B
Debt
$1.22B
Equity
$820.84M
Working capital
$356.86M
Debt to equity
1.49
Current ratio
1.62
Quick ratio
0.88
Net debt/EBITDA
2.72
Margins
Efficiency
Dividend
EBITDA margin
24.8%
Gross margin
55%
Net margin
12.3%
Operating margin
14.6%
Return on assets
6.7%
Return on equity
19.1%
Return on invested capital
11.1%
Return on capital employed
11.8%
Return on sales
16.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
HAE stock price
How has the Haemonetics stock price performed over time
Intraday
0%
1 week
3.03%
1 month
9.1%
1 year
-20.78%
YTD
-10.78%
QTD
9.61%
Financial performance
How have Haemonetics's revenue and profit performed over time
Revenue
$1.36B
Gross profit
$748.96M
Operating income
$198.8M
Net income
$167.68M
Gross margin
55%
Net margin
12.3%
HAE's net income is up by 43% year-on-year and by 29% since the previous quarter
The net margin is up by 37% year-on-year and by 29% since the previous quarter
The operating income is up by 21% year-on-year and by 10% since the previous quarter
The operating margin has grown by 16% YoY and by 11% from the previous quarter
Price vs fundamentals
How does HAE's price correlate with its fundamentals
Growth
What is Haemonetics's growth rate over time
Valuation
What is Haemonetics stock price valuation
P/E
20.92
P/B
4.26
P/S
2.58
EV/EBIT
19.22
EV/EBITDA
12.64
EV/Sales
3.13
The price to earnings (P/E) is 59% lower than the 5-year quarterly average of 50.7 and 30% lower than the last 4 quarters average of 29.7
The company's EPS rose by 44% YoY and by 30% QoQ
The price to book (P/B) is 18% lower than the 5-year quarterly average of 5.2 and 3.2% lower than the last 4 quarters average of 4.4
The equity has declined by 14% year-on-year and by 9% since the previous quarter
The stock's P/S is 32% less than its 5-year quarterly average of 3.8 and 8% less than its last 4 quarters average of 2.8
The revenue rose by 4% YoY
Efficiency
How efficient is Haemonetics business performance
HAE's return on equity is up by 49% year-on-year and by 35% since the previous quarter
The company's return on sales rose by 29% YoY and by 24% QoQ
The company's return on assets rose by 26% QoQ and by 20% YoY
The company's return on invested capital rose by 19% QoQ and by 2.8% YoY
Dividends
What is HAE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for HAE.
Financial health
How did Haemonetics financials performed over time
The total assets is 50% more than the total liabilities
The current ratio has plunged by 59% from the previous quarter and by 37% YoY
The company's quick ratio has shrunk by 58% QoQ and by 31% YoY
The debt is 49% greater than the equity
The debt to equity has soared by 77% YoY and by 10% from the previous quarter
The debt has soared by 52% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.